AstraZeneca (AZN) DIvidends Date & History

Key Takeaways

• AstraZeneca offers a trailing dividend yield of 1.66% and forward yield of 1.67%, paid semi-annually at $3.20 per share annually.
• Progressive dividend policy supports modest annual increases, with a 3% rise to $3.20 for 2025.
• Payout ratio of 47.91% signals strong coverage by earnings.
• Cash flows adequately cover dividends, bolstering sustainability amid solid financials.
• Yield trails pharmaceutical peers but appeals to investors prioritizing stability and growth.
• Recent ex-dividend date was February 20, 2026, with payment on March 23, 2026.

Dividend Overview

AstraZeneca (AZN), a leading global pharmaceutical company, maintains a progressive dividend policy aimed at delivering sustainable growth or maintenance of payouts aligned with long-term earnings prospects. The company distributes dividends semi-annually, with the larger second interim payment typically announced alongside full-year results in February and paid in March, and the first interim following half-year results in August and paid in September. The current trailing annual dividend stands at $3.20 per share, delivering a yield of 1.66%, while the forward yield is 1.67%. This positions AZN as a modest dividend payer rather than a high-yield stock, emphasizing balance between shareholder returns, reinvestment in R&D, and preserving an investment-grade credit rating. Investors value its consistency in a volatile biotech and pharma landscape.

Dividend History and Growth

AstraZeneca has demonstrated reliable dividend payments over decades, with no recent cuts and a focus on gradual progression. Recent history shows semi-annual payouts: $2.17 (final for 2025, ex-date February 20, 2026), $1.03 (interim 2025, ex-date August 7, 2025), $2.10 (final 2024), and $1.00 (interim 2024), totaling $3.20 annually—a 3% increase from $3.10 in 2024. Earlier years reflect steady growth: $3.10 (2024), approximately $3.00+ in 2023, with first interim dividends rising from $0.90 in prior years to $1.00-$1.03 recently. Over five years, dividend growth averages around 2.6%, supported by revenue expansion from oncology and rare disease portfolios. The policy prioritizes long-term strategy over aggressive hikes, ensuring consistency without straining finances.

Dividend Sustainability and Payout Ratio

AstraZeneca's dividend appears highly sustainable, underpinned by a payout ratio of 47.91%—comfortably below 60%, leaving ample room for reinvestment and buffers. Earnings per share (EPS) robustly cover the dividend, while free cash flow (FCF) provides additional support, with cash payout ratios around 55%. The company ended 2025 with net debt of $23.4 billion but maintains strong credit ratings (Moody's A1, S&P A-), reflecting prudent leverage. Progressive policy ties increases to underlying business performance, including R&D investments and pipeline successes. With forecasted sales and profit growth into 2026, AZN balances returns and growth, minimizing cut risks.

Dividend Compared to Industry Peers

In the pharmaceutical sector, AstraZeneca's 1.66% yield is modest compared to peers. PFE (Pfizer) offers around 6.4%, driven by higher payouts post-patent cliffs, while JNJ (Johnson & Johnson) yields about 3%, and Novartis ~2.7%, Roche 2.8%, and Merck 2.7%. Sector averages hover near 2-3%, with AZN's lower yield reflecting its emphasis on growth via innovation over income maximization. This profile suits investors favoring capital appreciation alongside dividends over pure yield plays.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener excels at identifying dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to uncover hidden gems like sustainable dividend payers in pharma.

Is This Stock Attractive for Dividend Investors?

AstraZeneca appeals to dividend investors seeking stability and modest income within a high-growth pharmaceutical powerhouse, rather than ultra-high yields. Its 1.7% yield, backed by a low 48% payout ratio and consistent semi-annual payments, suits conservative long-term holders prioritizing reliability over aggressive income. Dividend growth investors may appreciate the progressive policy and recent 3% hikes, tied to expanding revenues from blockbuster drugs in oncology and cardiovascular areas. However, those chasing yields above 4% might look elsewhere, as AZN reinvests heavily in R&D (research and development), potentially driving share price appreciation. Balanced portfolios blending growth and income could benefit, given strong FCF coverage and investment-grade status, though sector risks like patent expirations warrant monitoring. Overall, it fits patient investors valuing pharma resilience.

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.